Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 7250-43-3 Chemical Structure| 7250-43-3

Structure of 7250-43-3

Chemical Structure| 7250-43-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Ouellette, Vincent ;

Abstract: Cancer is a major public health concern and represents the leading cause of death in Canada. Approximately two out of five Canadians will be diagnosed with cancer during their lifetime and one out of four will die from it. Despite advances in treatments, cancer remains a challenging disease to treat still claiming lives today. Therefore, it is imperative to develop new treatments to treat this lethal disease. As a result, my doctoral project primarily focuses on the development of two new families of anticancer agents: 1) antimicrotubule prodrugs targeting breast cancer cells expressing cytochrome P450 1A1 (CYP1A1) designated as N-alkyl phenylimidazolidones (AIMZs), and 2) dihydroorotate dehydrogenase (DHODH) inhibitors targeting acute myeloid leukemia (AML) cells named N-phenyl ureidobenzenesulfonates (PUB-SOs). One of the predominant issues during the development of new drugs is the water solubility of the newly prepared molecules and unfortunately our compounds are not exempt from this problem. Moreover, salt formation is an essential strategy used in the pharmaceutical industry to improve this property. In this context, we proposed that salt formation increases the water solubility of our compounds without altering their biological properties. Therefore, the main objective of my doctoral project was to design, prepare, and evaluate the physicochemical and biological properties of new AIMZs, PUB-SOs and their salts to optimize their biopharmaceutical properties. It is divided into three main phases: 1) design, synthesis, and characterization of AIMZs and PUB-SOs and their salts, 2) evaluation of their physicochemical and biological properties using various biofunctional assays, and 3) pharmacokinetic evaluation of the two best candidates in a mouse model. To this end, over 100 new derivatives and analogues of AIMZs and PUB-SOs were designed and prepared by adding an ionisable function to their molecular architecture to enable salt formation. They were subsequently chemically characterized and biologically evaluated. First, the new AIMZs and their salts exhibit potent antiproliferative activity in the nanomolar to low micromolar range and significant selectivity against breast cancer cells expressing CYP1A1. Moreover, the most potent compounds arrest cell cycle progression in the G2/M phase, inhibit microtubule polymerization, and disrupt the cytoskeleton by binding to the colchicine-binding site. They are also bioactivated by CYP1A1 microsomes into their potent antimitotic derivatives by N-dealkylation and exhibit suitable physicochemical properties and in vitro hepatic stability profiles for in vivo studies. Second, the new PUB-SOs and their salts show antiproliferative activity ranging from hundreds of nanomolar to low micromolar on AML cell lines. The most potent compounds arrest the cell cycle in the S-phase and induce phosphorylation of histone H2AX, a marker of replicative stress. They inhibit DHODH activity, induce differentiation of leukemia cells, and exhibit physicochemical properties and hepatic stability profiles on murine and human liver microsomes suitable for animal studies. The new salts of both families exhibit higher solubility compared to their corresponding neutral counterparts without altering their biological activity. Finally, the half-life (t1/2) of the two most promising salts of PUB-SO derivatives were evaluated in a healthy female CD-1 mice. Both compounds showed t1/2 in the range of ten minutes. Overall, my project has enabled the preparation of new AIMZ and PUB-SO analogues and their salts with improved aqueous solubility while retaining their biological activity and an adequate physicochemical properties profile. These results highlight that salt formation on the chemical structure of AIMZs and PUB-SOs is an appropriate strategy to improve the water solubility and facilitate the formulation of these compounds. Nonetheless, further studies will need to be performed to understand and improve their short t1/2. My work will ultimately contribute to the optimization of more effective and less toxic therapies to improve the quality of life for patients with breast and leukemia cancers.

Purchased from AmBeed: ;

Alternative Products

Product Details of [ 7250-43-3 ]

CAS No. :7250-43-3
Formula : C6H10I2N2O2
M.W : 395.96
SMILES Code : O=C(NCCNC(CI)=O)CI
MDL No. :MFCD00728185

Safety of [ 7250-43-3 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H314
Precautionary Statements:P264-P270-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P310-P330-P331-P363-P403+P233-P501
Class:8
UN#:3261
Packing Group:
 

Historical Records